Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A targeted combination therapy achieves effective pancreatic cancer regression and prevents tumor resistance.

Proceedings of the National Academy of Sciences of the United States of America - 9 Jun 2026

Liaki Vasiliki, Barrambana Sara, Kostopoulou Myrto, Lechuga Carmen G, Zamorano-Dominguez Elena, Acosta-Gallego Domingo, Morales-Cacho Lucía, Álvarez Ruth, Sun Pian, Rosas-Perez Blanca, Barrero Rebeca, Jiménez-Parrado Silvia, López-García Alejandra, San Roman Marta, López-Gil Juan Carlos, Drosten Matthias, Sainz Bruno, Musteanu Monica, Caleiras Eduardo, Dusetti Nelson, Poli Valeria, Sánchez-Bueno Francisco, Guerra Carmen, Barbacid Mariano

Abstract excerpt

Pancreatic ductal adenocarcinoma (PDAC) has one of the lowest cancer survival rates. Recent studies using RAS inhibitors have opened the door to more efficacious therapies although their beneficial effect is still limited mainly due to the rapid appearance of tumor resistance. Here, we demonstrate that genetic ablation of three independent nodes involved in downstream (RAF1), upstream (EGFR), and orthogonal...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Pancreatic Ductal

Share to Drug Resistance, Neoplasm

Share to ErbB Receptors

Share to Pancreatic Neoplasms

Share to Proto-Oncogene Proteins p21(ras)

Share to STAT3 Transcription Factor

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 42224594
DOI: 10.1073/pnas.2610708123
PMCID: PMC13250540

Genes

EGFR
KRAS
STAT3
RAF1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A targeted combination therapy achieves effective pancreatic cancer regression and prevents tumor resistance.PMID 42224594Read ↗

A TARGETED COMBINATION THERAPY ACHIEVES EFFECTIVE PANCREATIC CANCER REGRESSION AND PREVENTS TUMOR RESISTANCESemantic proximity Read ↗

KRAS Pathway-based Therapeutic Approaches in Pancreatic Cancer.Semantic proximity Read ↗

Navigating the complexities of pancreatic ductal adenocarcinoma: A review on therapeutic models and RAS inhibitors.Semantic proximity Read ↗

ADT-1004: a first-in-class, oral pan-RAS inhibitor with robust antitumor activity in preclinical models of pancreatic ductal adenocarcinoma.Semantic proximity Read ↗

Overcoming Adaptive Resistance to KRAS and MEK Inhibitors by Co-targeting mTORC1/2 Complexes in Pancreatic Cancer.Semantic proximity Read ↗

Dual Inhibition of KRASG12D and Pan-ERBB Is Synergistic in Pancreatic Ductal Adenocarcinoma.Semantic proximity Read ↗

Tumor-selective effects of active RAS inhibition in pancreatic ductal adenocarcinomaSemantic proximity Read ↗

Oncogenic Kras <sup>G12D</sup> specific non-covalent inhibitor reprograms tumor microenvironment to prevent and reverse early pre-neoplastic pancreatic lesions and in combination with immunotherapy regresses advanced PDAC in a CD8 <sup>+</sup> T cells dependent mannerSemantic proximity Read ↗

Recent Anti-KRASG12D Therapies: A “Possible Impossibility” for Pancreatic Ductal AdenocarcinomaSemantic proximity Read ↗

Triple Blockade of Oncogenic RAS Signaling Using KRAS and MEK Inhibitors in Combination with Irradiation in Pancreatic Cancer.Semantic proximity Read ↗

Key Considerations for Targeting KRAS in Pancreatic Cancer: Potential Impact on the Treatment Paradigm.Semantic proximity Read ↗

KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.